Cargando…

T cell abundance in blood predicts acute organ toxicity in chemoradiotherapy for head and neck cancer

Treatment of head and neck squamous cell carcinoma (HNSCC) by chemoradiotherapy (CRT) often results in high-grade acute organ toxicity (HGAOT). As these adverse effects impair the patients' quality of life and the feasibility of the planned therapy, we sought to analyze immunological parameters...

Descripción completa

Detalles Bibliográficos
Autores principales: Beschel, L. Milena, Leu, Martin, Reichardt, Sybille D., Rave-Fränk, Margret, Schirmer, Markus A., Stadelmann, Christine, Canis, Martin, Wolff, Hendrik A., Reichardt, Holger M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323201/
https://www.ncbi.nlm.nih.gov/pubmed/27589568
http://dx.doi.org/10.18632/oncotarget.11677
_version_ 1782509989145870336
author Beschel, L. Milena
Leu, Martin
Reichardt, Sybille D.
Rave-Fränk, Margret
Schirmer, Markus A.
Stadelmann, Christine
Canis, Martin
Wolff, Hendrik A.
Reichardt, Holger M.
author_facet Beschel, L. Milena
Leu, Martin
Reichardt, Sybille D.
Rave-Fränk, Margret
Schirmer, Markus A.
Stadelmann, Christine
Canis, Martin
Wolff, Hendrik A.
Reichardt, Holger M.
author_sort Beschel, L. Milena
collection PubMed
description Treatment of head and neck squamous cell carcinoma (HNSCC) by chemoradiotherapy (CRT) often results in high-grade acute organ toxicity (HGAOT). As these adverse effects impair the patients' quality of life and the feasibility of the planned therapy, we sought to analyze immunological parameters in tumor material and blood samples obtained from 48 HNSCC patients in order to assess the potential to predict the individual acute organ toxicity. T cells in the tumor stroma were enriched in patients developing HGAOT whereas levels of soluble factors in the plasma and gene expression in whole blood did not coincide with the occurrence of acute organ toxicity. In contrast, the frequency and absolute numbers of selected leukocyte subpopulations measured in samples of peripheral blood mononuclear cells (PBMCs) directly before the beginning of CRT were significantly different in patients with HGAOT as compared to those without. When we validated several potential markers including the abundance of T cells in a small prospective study with 16 HNSCC patients, we were able to correctly predict acute organ toxicity in up to 81% of the patients. We conclude that analysis of PBMCs by fluorescence-activated cell sorting (FACS) might be a convenient strategy to identify patients at risk of developing HGAOT caused by CRT, which might allow to adapt the treatment regimen and possibly improve disease outcome.
format Online
Article
Text
id pubmed-5323201
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53232012017-03-23 T cell abundance in blood predicts acute organ toxicity in chemoradiotherapy for head and neck cancer Beschel, L. Milena Leu, Martin Reichardt, Sybille D. Rave-Fränk, Margret Schirmer, Markus A. Stadelmann, Christine Canis, Martin Wolff, Hendrik A. Reichardt, Holger M. Oncotarget Research Paper Treatment of head and neck squamous cell carcinoma (HNSCC) by chemoradiotherapy (CRT) often results in high-grade acute organ toxicity (HGAOT). As these adverse effects impair the patients' quality of life and the feasibility of the planned therapy, we sought to analyze immunological parameters in tumor material and blood samples obtained from 48 HNSCC patients in order to assess the potential to predict the individual acute organ toxicity. T cells in the tumor stroma were enriched in patients developing HGAOT whereas levels of soluble factors in the plasma and gene expression in whole blood did not coincide with the occurrence of acute organ toxicity. In contrast, the frequency and absolute numbers of selected leukocyte subpopulations measured in samples of peripheral blood mononuclear cells (PBMCs) directly before the beginning of CRT were significantly different in patients with HGAOT as compared to those without. When we validated several potential markers including the abundance of T cells in a small prospective study with 16 HNSCC patients, we were able to correctly predict acute organ toxicity in up to 81% of the patients. We conclude that analysis of PBMCs by fluorescence-activated cell sorting (FACS) might be a convenient strategy to identify patients at risk of developing HGAOT caused by CRT, which might allow to adapt the treatment regimen and possibly improve disease outcome. Impact Journals LLC 2016-08-29 /pmc/articles/PMC5323201/ /pubmed/27589568 http://dx.doi.org/10.18632/oncotarget.11677 Text en Copyright: © 2016 Beschel et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Beschel, L. Milena
Leu, Martin
Reichardt, Sybille D.
Rave-Fränk, Margret
Schirmer, Markus A.
Stadelmann, Christine
Canis, Martin
Wolff, Hendrik A.
Reichardt, Holger M.
T cell abundance in blood predicts acute organ toxicity in chemoradiotherapy for head and neck cancer
title T cell abundance in blood predicts acute organ toxicity in chemoradiotherapy for head and neck cancer
title_full T cell abundance in blood predicts acute organ toxicity in chemoradiotherapy for head and neck cancer
title_fullStr T cell abundance in blood predicts acute organ toxicity in chemoradiotherapy for head and neck cancer
title_full_unstemmed T cell abundance in blood predicts acute organ toxicity in chemoradiotherapy for head and neck cancer
title_short T cell abundance in blood predicts acute organ toxicity in chemoradiotherapy for head and neck cancer
title_sort t cell abundance in blood predicts acute organ toxicity in chemoradiotherapy for head and neck cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323201/
https://www.ncbi.nlm.nih.gov/pubmed/27589568
http://dx.doi.org/10.18632/oncotarget.11677
work_keys_str_mv AT beschellmilena tcellabundanceinbloodpredictsacuteorgantoxicityinchemoradiotherapyforheadandneckcancer
AT leumartin tcellabundanceinbloodpredictsacuteorgantoxicityinchemoradiotherapyforheadandneckcancer
AT reichardtsybilled tcellabundanceinbloodpredictsacuteorgantoxicityinchemoradiotherapyforheadandneckcancer
AT ravefrankmargret tcellabundanceinbloodpredictsacuteorgantoxicityinchemoradiotherapyforheadandneckcancer
AT schirmermarkusa tcellabundanceinbloodpredictsacuteorgantoxicityinchemoradiotherapyforheadandneckcancer
AT stadelmannchristine tcellabundanceinbloodpredictsacuteorgantoxicityinchemoradiotherapyforheadandneckcancer
AT canismartin tcellabundanceinbloodpredictsacuteorgantoxicityinchemoradiotherapyforheadandneckcancer
AT wolffhendrika tcellabundanceinbloodpredictsacuteorgantoxicityinchemoradiotherapyforheadandneckcancer
AT reichardtholgerm tcellabundanceinbloodpredictsacuteorgantoxicityinchemoradiotherapyforheadandneckcancer